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In observational studies, several risk factors are prog-
nostic of disease outcomes in neuromyelitis optica 
spectrum disorder (NMOSD). Dietary or lifestyle fac-
tors associated with weight,1–4 delayed treatment from 
initial diagnosis or diagnostic delay,5,6 higher levels of 
disability or attack rates early in the disease course,1,7 
and being of non-White ethnicity8–13 were linked to 
disease outcomes.
N-MOmentum is a prospective, randomized, placebo-
controlled, double-masked trial of inebilizumab, an 
anti-CD19 monoclonal B-cell-depleting antibody, in 
patients with NMOSD.14 In N-MOmentum, the risk 
of an adjudicated NMOSD attack was significantly 
reduced with inebilizumab compared with placebo 
(hazard ratio (HR), 0.272, (95% confidence interval 
(CI): 0.150–0.496); p < 0.0001). Although the 
N-MOmentum study recruited participants who were 
seropositive and seronegative for aquaporin 4 autoan-
tibodies (AQP4-IgG), the majority of participants 
were AQP4-IgG seropositive, with only 17 partici-
pants (7.4%) who were AQP4-IgG seronegative.14
Pre-planned sensitivity and subgroup analyses used to 
test the robustness of the primary endpoint in 
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Background: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disor-
der (NMOSD) attack was significantly reduced with inebilizumab compared with placebo.
Objective: To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup 
analyses.
Methods: N-MOmentum is a prospective, randomized, placebo-controlled, double-masked trial of inebi-
lizumab, an anti-CD19 monoclonal B-cell-depleting antibody, in patients with NMOSD. Pre-planned and 
post hoc analyses were performed to evaluate the primary endpoint across a range of attack definitions 
and demographic groups, as well as key secondary endpoints.
Results: In the N-MOmentum trial (ClinicalTrials.gov: NCT02200770), 174 participants received ine-
bilizumab and 56 received placebo. Attack risk for inebilizumab versus placebo was consistently and 
significantly reduced, regardless of attack definition, type of attack, baseline disability, ethnicity, treat-
ment history, or disease course (all with hazard ratios < 0.4 favoring inebilizumab, p < 0.05). Analyses 
of secondary endpoints showed similar trends.
Conclusion: N-MOmentum demonstrated that inebilizumab provides a robust reduction in the risk of NMOSD 
attacks regardless of attack evaluation method, attack type, patient demographics, or previous therapy.
The N-MOmentum study is registered at ClinicalTrials.gov: NCT2200770.
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N-MOmentum (time to an adjudicated NMOSD attack) 
are presented. Data for key secondary endpoints are 
also presented.
Methods
Case selection and study population
Eligible participants were 18 years or older with an 
Expanded Disability Status Scale (EDSS) score of 8.0 
or less, with a documented history of one or more 
neuromyelitis optica acute attacks that required res-
cue therapy within the last year, or 2 or more such 
attacks within 2 years prior to screening AND either 
(a) positive serum anti-AQP4-IgG result at screening 
OR (b) negative serum anti-AQP4-IgG result at 
screening without evidence of brain lesion consistent 
with MS and also meeting clinical criteria for neuro-
myelitis optica.15 AQP4-IgG seronegative subjects 
were reviewed by an independent eligibility commit-
tee for eligibility. Participants were randomly assigned 
(3:1) to receive inebilizumab 300 mg i.v. or placebo 
on days 1 and 15, with no other immune treatments 
allowed (Figure 1).14
The randomized controlled period (RCP) was 28 
weeks or up to an adjudicated attack. Attacks were 
evaluated using predefined attack diagnosis criteria 
that were developed specifically for this study.16 
Study investigators and an independent adjudication 
committee (AC) composed of three members assessed 
attacks.14 The primary endpoint was the time to an 
adjudicated attack; secondary endpoints included 
worsening from baseline in EDSS score at last visit, 
cumulative number of active magnetic resonance 
imaging (MRI) lesions (new gadolinium-enhancing 
T1 or new/enlarging T2), hospitalizations during the 
RCP, and change from baseline in low-contrast visual 
acuity binocular score.14 Only attacks confirmed by 
an AC majority (at least 2/3) were used for the pri-
mary endpoint analysis; participants with events adju-
dicated as non-attacks continued in the RCP. The RCP 
ended if participants experienced an adjudicated 
attack, reached day 197, or were in the RCP when 
enrollment stopped.14 Participants could then con-
tinue treatment in the open-label period for at least 1 
year, during which they received inebilizumab 300 
mg every 26 weeks to maintain B-cell depletion.14 
Eligibility criteria, settings and locations, sample size 
determination, and full details of interventions are 
available in the original publication of the 
N-MOmentum trial results,14 and the full trial proto-
col is available from: https://ucsf.box.com/s/
qn2uiij5lfxqj6h8ch2edkb2o9nzr9le.
Sensitivity and subgroup analyses
Sensitivity analyses were performed to assess whether 
the primary endpoint remained significant when 
accounting for various factors, and included: analysis 
Figure 1. N-MOmentum study design.
IDMC: Independent Data Monitoring Committee; NMOSD: neuromyelitis optica spectrum disorder; RCP: randomized controlled 
period.
N-MOmentum was a double-blind, placebo-controlled study at 99 medical centers in 25 countries, with a time-to-event design. End 
of RCP was defined as 67 NMOSD attacks, or when 252 participants had been randomized and had received study drug, whichever 
happened first. Enrollment was stopped early at 231 participants and 43 attacks owing to proven efficacy as determined by the IDMC. 
No background immunotherapy was permitted. The primary endpoint was the time to an NMOSD adjudicated attack within the RCP.
aParticipants eligible for the open-label period at the end of the RCP or after an adjudicated attack.
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of attacks only by unanimous AC decision, investiga-
tor-determined attacks, patient-reported symptoms, 
attacks including patients who discontinued prema-
turely, attacks categorized according to attack type, 
attacks adjusted for historical acute attacks and base-
line EDSS score, and censoring of attacks during the 
first 15 days of the trial. These analyses were pre-
planned and conducted for both the whole population 
and the AQP4-IgG seropositive population.
The primary endpoint was also analyzed across the 
following subgroups, where all characteristics are 
presumed to reflect disease severity or differential 
prognoses: disease duration (<5 years or ⩾5 years, 
from time of clinical diagnosis), time since last 
attack at enrollment (<26 weeks or ⩾26 weeks), 
number of previous attacks (<4 attacks or ⩾4 
attacks), baseline EDSS score (<5 or ⩾5), use of 
prior immunosuppressive therapy (yes/no), White 
and non-White participants, Asian and non-Asian 
participants, underweight/healthy weight (<25 kg/
m2) and overweight/obese participants (⩾25 kg/m2). 
The cutoff disease duration of ⩾ 5 years was chosen 
to reflect those with longer-term disease and the time 
since last attack of 26 weeks is representative of the 
length of the RCP. Originally, a cutoff of 2 previous 
attacks was chosen to reflect the inclusion criteria 
(⩾2 attacks in the previous 2 years). As the number 
of previous attacks experienced by participants was 
typically greater than this, a new cutoff of ⩾ 4 
attacks was selected to be more representative of the 
population. A baseline EDSS score ⩾ 5 was selected 
as this represents the point where daily activities are 
impacted to a degree that requires special provi-
sions. The same subgroup analyses were performed 
for attack-related outcomes, including the cumula-
tive number of active (new gadolinium-enhancing 
T1 or new/enlarging T2) MRI lesions and the cumu-
lative number of NMOSD-related inpatient hospi-
talizations seen in participants during the RCP.
Statistical analysis
All sensitivity and subgroup analyses of NMOSD 
attacks were analyzed by Cox proportional hazards 
regression with placebo as the reference group, and 
treatment and serotype as explanatory factors. 
Interaction tests for the subgroup analyses were also 
performed, where p > 0.05 indicates no statistically 
significant difference in treatment effect between 
subgroups. The rate ratio for the cumulative number 
of active MRI lesions from baseline and the cumula-
tive number of NMOSD-related inpatient hospitali-
zations from baseline were assessed using negative 
binomial regression, with treatment and serostatus 
as explanatory variables.14 Because of the low num-
ber of participants in many of the subgroups, the sta-
tistical power to detect significant differences in the 
secondary sensitivity analyses is limited.
Standard protocol approvals, registrations, and 
patient consents
Institutional review boards or ethics committees at 
each study site approved the protocol. All participants 
provided written informed consent. The study was 
conducted in accordance with the provisions of the 
International Conference on Harmonization Guidelines 
for Good Clinical Practice and the principles of the 
Declaration of Helsinki. The study is registered with 
ClinicalTrials.gov, number NCT02200770.
Data availability statement
Reasonable requests for anonymized data on defined 
study outcomes will be made available by request. 
Proposals should be directed to katze@vielabio.com. 
Requestors will be required to sign a data access 
agreement. Requests will be considered for up to 3 
years after article publication.
Results
Participants
Of the 467 participants screened, 231 were rand-
omized; 175 were assigned to inebilizumab (with 
one participant not dosed) and 56 to placebo (overall 
population) (Figure 2). In the subgroup of partici-
pants who were AQP4-IgG seropositive, 161 were 
randomized to inebilizumab and 52 to placebo. 
Baseline demographics and characteristics were 
generally similar between treatment groups in the 
overall population and in AQP4-IgG seropositive 
participants.14
No notable differences in previous therapies for 
NMOSD were observed between treatment groups, 
with almost all participants receiving some form of 
prior medication or therapy for NMOSD (inebili-
zumab: 172/174 (98.9%); placebo: 55/56 (98.2%)). 
Similar numbers of participants had previously 
received intravenous immunoglobulin (inebilizumab: 
8/174 (5.4%); placebo: 3/56 (4.6%)) or immunosup-
pressive therapies (inebilizumab: 82/174 (47.1%); 
placebo: 26/56 (46.4%)) prior to enrollment, such as 
azathioprine (inebilizumab: 65/174 (37.4%); placebo: 
22/56 (39.3%)), mycophenolate (inebilizumab: 
27/174 (21.8%); placebo: 7/56 (12.5%)) or rituximab 
(inebilizumab: 13/174 (7.5%); placebo: 4/56 (7.1%)).
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Sensitivity and subgroup analyses of time to 
adjudicated attack
According to majority AC decision, 21 of the 174 par-
ticipants (12.1%) who received inebilizumab and 22 
of the 56 (39.3%) who received placebo experienced 
attacks. The risk reduction for inebilizumab versus 
placebo was 72.8% (HR, 0.272 (95% CI: 0.150–
0.496); p < 0.0001).14 The reduction in the risk of 
attack with inebilizumab versus placebo was signifi-
cant in all sensitivity and subgroup analyses (Figure 
3). The HR for all sensitivity and subgroup analyses 
was ⩽ 0.4 in the inebilizumab group compared with in 
the placebo group.
Risk of attack was reduced in the inebilizumab group 
compared with the placebo group when attacks were 
limited to unanimous AC decisions, investigator- 
determined attacks, or when participants reported 
attack symptoms. A reduction in attack risk was also 
seen for participants who prematurely discontinued the 
study, and for attacks based solely on clinical attack cri-
teria. When the definition of attacks was broadened to 
include events that required clinical intervention (such 
as intravenous corticosteroids, intravenous immuno-
globulin, and/or plasma exchange), but may not have 
fully met the attack criteria, the risk of attacks was still 
reduced in the inebilizumab group. Risk of attacks in 
the inebilizumab group compared with the placebo 
group was reduced for optic neuritis attacks and for spi-
nal cord attacks. Brainstem attacks (two in the placebo 
group and none in the inebilizumab group) occurred 
too infrequently for statistical analysis. Attack risk was 
lower in the inebilizumab group than in the placebo 
group when attacks that occurred on or before day 15 
were censored (two in the inebilizumab group and 
three in the placebo group). When adjusted by the num-
ber of historical NMOSD attacks and baseline EDSS 
score, the reduction in attack risk was maintained in the 
inebilizumab group. Reduction in the risk of attack 
with inebilizumab was observed in all sensitivity and 
subgroup analyses in the AQP4-IgG seropositive popu-
lation (HR ⩽ 0.4; p ⩽ 0.0016) (Figure 4), which is not 
unexpected based on the small proportion of partici-
pants who were AQP4-IgG seronegative. Only 17/230 
study participants (7.4%) were AQP4-IgG seronega-
tive, and therefore could not be analyzed statistically as 
Figure 2. CONSORT flow diagram.
CONSORT: Consolidated Standards of Reporting Trials; i.v.: intravenous; RCP: randomized controlled period.
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an independent subgroup. Details and post hoc analy-
ses of the AQP4-IgG seronegative subgroup are the 
subject of a separate manuscript.
Efficacy among demographic groups
The time to adjudicated attack was analyzed across a 
variety of demographic subgroups to investigate 
whether inebilizumab is equally effective in patients 
with different ethnicity, weight, disease course, and 
treatment history. The HR of inebilizumab treatment 
versus placebo was < 0.4 for all demographic sub-
groups (all p < 0.05). Interaction tests were p > 0.05 
in all cases (Figure 5). Risk of attack was reduced in 
participants receiving inebilizumab regardless of 
disease duration, attack occurrence within 6 months 
of study entry, or attack number before screening. 
Inebilizumab efficacy was not influenced by base-
line EDSS score, race, weight, or prior immunosup-
pressive maintenance therapy.
Figure 3. Sensitivity analyses for primary endpoint (time to adjudicated attack; overall population).
AC: adjudication committee; CI: confidence interval; EDSS: Expanded Disability Status Scale; HR: hazard ratio; NMOSD: 
neuromyelitis optica spectrum disorder.
Based on Cox regression method, with placebo as the reference group.
Figure 4. Sensitivity analyses for primary endpoint (time to adjudicated attack; AQP4-IgG seropositive population).
AC: adjudication committee; AQP4-IgG: aquaporin-4 immunoglobulin G; CI: confidence interval; EDSS: Expanded Disability Status 
Scale; HR: hazard ratio; NMOSD: neuromyelitis optica spectrum disorder.
Based on Cox regression method, with placebo as the reference group.
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Subgroup analyses of secondary endpoints
Subgroup analyses were conducted for the attack-
related secondary endpoints of the cumulative num-
bers of active MRI lesions (Table 1) and 
NMOSD-related inpatient hospitalizations during the 
RCP (Table 2). MRI scans were performed at base-
line, during attacks, and at the end of the RCP. 
Therefore, cumulative new lesions would be assessed 
in participants either at the time of an adjudicated 
attack during the RCP or at day 197. Rate ratio point 
estimates favored inebilizumab in all cases. 
Inebilizumab treatment appeared to be associated 
with significantly fewer new central nervous system 
(CNS) MRI lesions in participants with baseline 
EDSS scores less than 5, four or more attacks before 
study entry, a disease duration of less than 5 years, 
with a time to last attack before enrollment of at least 
26 weeks, or who were White, non-Asian, over-
weight/obese or had previously received prior immu-
nosuppressive maintenance therapy. Significant 
effects were not identified in the other corresponding 
subgroups, namely in participants with a disease 
duration of equal to or more than 5 years, baseline 
EDSS score of equal to or more than 5, fewer than 4 
previous NMOSD attacks, time to attack before 
enrollment of less than 26 weeks, or who were non-
White, Asian, underweight or healthy weight, or had 
previously not received immunosuppressive mainte-
nance therapy.
This lack of significance may possibly be related to 
smaller numbers of participants in these subgroups. 
Indeed, interaction tests detected no significant differ-
ences in treatment effect between the dichotomized 
groups (Table 1, all p > 0.05). The overall number of 
participants who had NMOSD-related inpatient hos-
pitalizations was low in both groups (inebilizumab, 
n = 10; placebo, n = 8). As such, meaningful point 
estimates of rate ratios and p values could not be cal-
culated, but the proportion of patients who required 
inpatient hospitalization was generally lower with 
inebilizumab (Table 2). Disability endpoint analyses 
are presented in a separate manuscript.
Discussion
In N-MOmentum, inebilizumab consistently provided 
a statistically significant reduction in the risk of attacks 
compared with placebo, regardless of who evaluated or 
reported attacks, whether decisions were based on clin-
ical criteria alone, and when considering anatomical 
attack locations separately. These results suggest that 
the result for the primary endpoint was robust and 
insensitive to these potential confounders; indeed, the 
study was designed to maximize clinically informative 
data by using independent AQP4-IgG seronegative 
patient eligibility-, attack adjudication-, and data mon-
itoring-committees,14,16 and establishing predefined 
attack criteria.16 However, it is also important to note 
Figure 5. Primary endpoint by demographic and baseline characteristic subgroup (time to adjudicated attack; overall 
population).
CI: confidence interval; EDSS: Expanded Disability Status Scale; HR: hazard ratio; NMOSD: neuromyelitis optica spectrum disorder.
Based on Cox regression method, with placebo as the reference group.
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Table 1. Subgroup analyses of key secondary endpoints: cumulative number of active MRI lesions, randomized controlled period.









RR (95% CI) p value Interaction 
test p value
Disease duration < 5 years 25/46 2.3 (1.2) 64/144 1.6 (1.0) 0.555 (0.363–0.849) 0.0066 0.8462
Disease duration ⩾ 5 years 7/10 2.3 (1.7) 15/30 1.9 (1.1) 0.603 (0.259–1.406) 0.2419
Baseline EDSS score < 5 22/39 2.5 (1.4) 59/129 1.6 (1.0) 0.538 (0.341–0.848) 0.0076 0.6901
Baseline EDSS score ⩾ 5 10/17 2.0 (1.1) 20/45 1.7 (0.9) 0.643 (0.319–1.295) 0.2163
Prior NMOSD attacks < 4 16/31 1.9 (1.1) 39/93 1.6 (1.0) 0.650 (0.372–1.139) 0.1322 0.4503
Prior NMOSD attacks ⩾ 4 16/25 2.8 (1.3) 40/81 1.7 (1.0) 0.484 (0.288–0.813) 0.0061
Time to last attack < 26w 17/33 2.3 (1.3) 48/103 1.6 (0.9) 0.645 (0.378–1.062) 0.0844 0.4460
Time to last attack ⩾ 26w 15/23 2.3 (1.3) 31/71 1.7 (1.2) 0.476 (0.265–0.855) 0.0130
White 15/28 2.3 (1.3) 37/92 1.3 (0.5) 0.428 (0.254–0.722) 0.0015 0.1887
Non-White 17/28 2.4 (1.3) 42/82 1.9 (1.3) 0.709 (0.416–1.209) 0.2065
Asian 6/8 1.7 (0.8) 21/39 2.0 (1.1) 0.886 (0.385–2.043) 0.7772 0.2638
Non-Asian 26/48 2.5 (1.3) 58/135 1.5 (1.0) 0.489 (0.318–0.752) 0.0011
Underweight/healthy 15/29 2.5 (1.4) 39/95 1.9 (1.3) 0.584 (0.316–1.080) 0.0864 0.8479
Overweight/obese 17/27 2.1 (1.2) 38/77 1.4 (0.6) 0.543 (0.344–0.859) 0.0090
Prior maintenance therapy, yes 23/38 2.3 (1.3) 56/114 1.7 (1.0) 0.609 (0.393–0.944) 0.0265 0.5903
Prior maintenance therapy, no 9/18 2.4 (1.3) 23/60 1.5 (1.1) 0.493 (0.236–1.030) 0.5930
CI: confidence interval; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; NMOSD: neuromyelitis optica spectrum disorder;  
RR: rate ratio; SD: standard deviation; w: weeks.
Table 2. Subgroup analyses of key secondary endpoints: cumulative number of NMOSD-related inpatient hospitalizations, randomized 
controlled period.









Disease duration < 5 years 6/46 (13.0%) 1.5 (0.8) 6/144 (4.2%) 1.0 (0.0)
Disease duration ⩾ 5 years 2/10 (20.0%) 1.0 (0.0) 4/30 (13.3%) 1.0 (0.0)
Baseline EDSS score < 5 5/39 (12.8%) 1.6 (0.9) 6/129 (4.7%) 1.0 (0.0)
Baseline EDSS score ⩾ 5 3/17 (17.6%) 1.0 (0.0) 4/45 (8.9%) 1.0 (0.0)
Prior NMOSD attacks < 4 5/31 (16.1%) 1.6 (0.9) 2/93 (2.2%) 1.0 (0.0)
Prior NMOSD attacks ⩾ 4 3/25 (12.0%) 1.0 (0.0) 8/81 (9.9%) 1.0 (0.0)
Time to last attack < 26w 1/33 (3.0%) 1.0 (0.0) 7/103 (6.8%) 1.0 (0.0)
Time to last attack ⩾ 26w 7/23 (30.4%) 1.4 (0.8) 3/71 (4.2%) 1.0 (0.0)
White 3/28 (10.7%) 1.3 (0.6) 6/92 (6.5%) 1.0 (0.0)
Non-White 5/28 (17.9%) 1.4 (0.9) 4/82 (4.9%) 1.0 (0.0)
Asian 1/8 (12.5%) 1.0 (0.0) 2/39 (5.1%) 1.0 (0.0)
Non-Asian 7/48 (14.6%) 1.4 (0.8) 8/135 (5.9%) 1.0 (0.0)
Underweight/heathy 2/29 (6.9%) 1.0 (0.0) 7/95 (7.4%) 1.0 (0.0)
Overweight/obese 6/27 (22.2%) 1.5 (0.8) 3/77 (3.9%) 1.0 (0.0)
Prior maintenance therapy, yes 6/38 (15.8%) 1.5 (0.8) 6/114 (5.3%) 1.0 (0.0)
Prior maintenance therapy, no 2/18 (11.1%) 1.0 (0.0) 4/60 (6.7%) 1.0 (0.0)
NMOSD: neuromyelitis optica spectrum disorder; SD: standard deviation; w: weeks; EDSS: Expanded Disability Status Scale.
aThe numbers of cases were too low to generate meaningful rate ratios or statistical analyses for these outcomes.
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that a robust treatment effect was observed, even 
according to metrics that were more in line with the 
general clinical setting (investigator-determined attacks 
or patient-reported symptoms, attacks adjudicated by 
attack criteria solely using clinical data). As such, while 
the methods employed in N-MOmentum may help to 
inform future trial design in NMOSD, more impor-
tantly, they provide meaningful information to support 
clinicians in making treatment decisions.
Attacks in NMOSD tend to cluster,17 and therefore 
attacks are more likely to occur in patients beginning 
a new program of treatment if they have had frequent 
recent attacks. It is important to note that inebili-
zumab was effective regardless of whether partici-
pants had relapses within 6 months of enrollment, 
showing treatment benefit regardless of whether par-
ticipants had recent attacks.
Inebilizumab also provided a statistically significant 
reduction in the risk of attacks compared with pla-
cebo across a broad spectrum of baseline characteris-
tics and demographics, demonstrating efficacy 
regardless of ethnicity, body habitus, previous treat-
ment, or disease duration. Subgroup analyses of 
cumulative numbers of new CNS MRI lesions sup-
ported the efficacy of inebilizumab in the same sub-
groups, and the proportion of participants who 
required NMOSD-related hospitalizations was gen-
erally lower with inebilizumab. Given that these sec-
ondary endpoints are related to attacks (new MRI 
lesions typically occur during attacks and NMOSD-
related hospitalizations occur with severe attacks), 
the subgroup analyses for these secondary endpoints 
bolster the sensitivity and subgroup analyses con-
ducted on the primary endpoint.
Although carefully designed to make interpretation of 
results relatively straightforward, the N-MOmentum 
study had several limitations.7 Of relevance to the 
sensitivity and subgroup analyses reported here, these 
include: the small number of AQP4-IgG seronegative 
participants; the exclusion of patients with several 
comorbidities or laboratory abnormalities for partici-
pant safety (which may reduce the extent to which the 
trial participants are representative of the general 
NMOSD population); and the relatively small size of 
the study population, which, nevertheless, constitutes 
the largest prospective randomized study to be con-
ducted in NMOSD. Criteria for the pre-planned sub-
group analyses could have been chosen to be more 
representative of the actual cohort recruited. In the 
N-MOmentum trial, the Bonferroni-based chain pro-
cedure was used to control the overall type 1 error rate 
for the primary and key secondary endpoints.14 This 
rigorous correction for multiple comparisons was 
not performed for the analyses presented here. 
Nonetheless, that all of the sensitivity analyses of the 
primary endpoint were pre-planned, lends some con-
fidence to the results.
The relatively small size of the study was reflected in 
the small size of the subgroups analyzed for second-
ary endpoints. Even where these subgroups were rela-
tively large (e.g. non-White participants or healthy/
underweight participants, Table 1), further division by 
treatment group reduced the number of subjects avail-
able for analysis. It should be noted that rate ratio 
point estimates and 95% CIs, which are demonstra-
tive of the actual size of treatment effect, favored 
inebilizumab in all cases. While the results presented 
here are promising, and may help inform treatment 
decisions by clinicians, further studies designed to 
investigate the effect of baseline or demographic 
characteristics on inebilizumab treatment efficacy are 
needed, including in patient populations at risk of 
more severe disease.
The results of the N-MOmentum study demonstrate 
that inebilizumab provides a robust reduction in the 
risk of attacks in patients with NMOSD, regardless of 
attack evaluation methods, attack types, patient demo-
graphics, and previous therapies. These findings pro-
vide important information for clinicians who are 
making treatment decisions for patients with NMOSD.
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